Modulation of Microbiota‐Derived Bile Acids Linked to Symptom Amelioration in Crohn's Disease: Insights From a Randomized Clinical Trial With Xanthohumol Supplementation
Molecular Nutrition & Food Research · 2026
DOI: 10.1002/mnfr.70501 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Molecular Nutrition & Food Research, 2026. Verfasst von Paige E Jamieson und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Nutrition and Public Health, Oregon State University, Corvallis, Oregon, USA. Hauptthemen laut MEDLINE: Bile Acids and Salts, Crohn Disease, Flavonoids, Gastrointestinal Microbiome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NCCIH NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Xanthohumol (XN), a dietary flavonoid from hops ( Humulus lupulus ), possesses anti‐inflammatory and microbiome‐modulatory properties with potential therapeutic benefits for Crohn's disease (CD). To investigate the effects of XN on the gut environment in CD, we conducted a randomized, placebo‐controlled clinical trial—the XN Microbiome and Signature (XMaS) trial (NCT4590508). 19 participants with clinically active CD completed the study. They were randomized to receive 24 mg/day of XN or placebo for 8 weeks, with clinical assessments at baseline and every 2 weeks. We assessed changes to Crohn's disease activity index (CDAI) scores, systemic inflammation, gut barrier function, profiling of microbial metabolism of XN, and gut microbiota composition and metabolism. Integration analysis of gut microbiota abundance, fecal metabolites, and inflammatory markers with CDAI scores revealed a pattern in which reductions in secondary bile acids and increases in IL‐10 were associated with improved CDAI score in XN‐treated individuals. These findings suggest that XN beneficially modulates the gut environment in CD by influencing microbial bile acid metabolism and host inflammatory response, thereby improving symptoms in individuals with severe innate immune activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Nutrition and Public Health, Oregon State University, Corvallis, Oregon, USA.
- Linus Pauling Institute, Oregon State University, Corvallis, Oregon, USA.
- Department of Pharmaceutical Sciences, Oregon State University, Corvallis, Oregon, USA.
- Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory, Richland, Washington, USA.
- Department of Chemistry, Oregon State University, Corvallis, Oregon, USA.
- Department of Microbiology, Oregon State University, Corvallis, Oregon, USA.
Förderung
- NIH HHS
- NCCIH NIH HHS
- National Institutes of Health
Zitieren
APA
Jamieson, P. E., Gu, I., Reichart, N. J., Maier, C. S., Ho, E., Sharpton, T. J., Metz, T. O., Bradley, R., & Stevens, J. F. (2026). Modulation of Microbiota‐Derived Bile Acids Linked to Symptom Amelioration in Crohn's Disease: Insights From a Randomized Clinical Trial With Xanthohumol Supplementation. Molecular Nutrition & Food Research. https://doi.org/10.1002/mnfr.70501
Vancouver
Jamieson PE, Gu I, Reichart NJ, Maier CS, Ho E, Sharpton TJ, et al. Modulation of Microbiota‐Derived Bile Acids Linked to Symptom Amelioration in Crohn's Disease: Insights From a Randomized Clinical Trial With Xanthohumol Supplementation. Molecular Nutrition & Food Research. 2026. doi:10.1002/mnfr.70501
BibTeX
@article{Jamieson2026,
author = {Jamieson, Paige E and Gu, Inah and Reichart, Nicholas J and Maier, Claudia S and Ho, Emily and Sharpton, Thomas J and Metz, Thomas O and Bradley, Ryan and Stevens, Jan F},
title = {Modulation of Microbiota‐Derived Bile Acids Linked to Symptom Amelioration in Crohn's Disease: Insights From a Randomized Clinical Trial With Xanthohumol Supplementation},
journal = {Molecular Nutrition & Food Research},
year = {2026},
doi = {10.1002/mnfr.70501}
}
EUVIMED